Low Testosterone Clinical Trials

A listing of Low Testosterone medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.

riociguat
adempas
pulmonary arterial hypertension
  • 0 views
  • 04 Aug, 2021
  • 13 locations
This Study Tests the Safety of Inhaled BAY1237592 How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure affecting the blood vessels in the lungs due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Pulmonary hypertension is characterized by the elevation of pressure in …

nitric oxide
prostaglandin
iloprost
chronic thromboembolic pulmonary hypertension
endothelin
  • 69 views
  • 04 Aug, 2021
  • 58 locations
A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH). The first part (Phase 2) will assess three different doses of MK-5475 compared to placebo; the treatment dose with the best efficacy and safety profile will be …

heart disease
left ventricular end-diastolic pressure
body mass index
right heart catheterization
pulmonary arterial hypertension
  • 0 views
  • 04 Aug, 2021
  • 17 locations
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

hypertension
angiotensin
beta-blocker
arginine
calcium channel blockers
  • 5462 views
  • 26 Jul, 2021
  • 297 locations
A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

Study ROR-PH-302, ADVANCE CAPACITY, is designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after 28 weeks of treatment

cardiopulmonary exercise testing
endothelin
diuretics
endothelin receptor antagonist
exercise stress test
  • 0 views
  • 29 Jul, 2021
  • 31 locations
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

A randomized, double-blind, placebo-controlled dose escalation and verification study to assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) versus placebo in subjects at risk for pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy. (REBUILD)

nitric oxide
vasodilator
pulmonary disease
dyspnea
idiopathic pulmonary fibrosis
  • 168 views
  • 04 Aug, 2021
  • 47 locations
Physiological-based Cord Clamping in Congenital Diaphragmatic Hernia

Pulmonary hypertension is a major determinant of postnatal survival in infants with a congenital diaphragmatic hernia (CDH). The current care during the perinatal stabilisation period in infants born with this rare birth defect might contribute to the development of pulmonary hypertension after birth - in particular umbilical cord clamping before …

hypertension
umbilical cord clamping
congenital diaphragmatic hernia
resuscitation
diaphragmatic hernia
  • 0 views
  • 04 Aug, 2021
  • 3 locations
Registration Study for Rare Type of Pulmonary Hypertension

The knowledge on the rare type of pulmonary hypertension which can not be explained by left heart disease, respiratory disease or congenital heart disease is very limited. Investigators aim to setup a national registration study for the rare type of pulmonary hypertension, to understand the natural history, survival, progression, genetic …

heart disease
pulmonary disease
right heart catheterization
pulmonary arterial hypertension
  • 1 views
  • 04 Aug, 2021
  • 1 location
Prospective Non-interventional Multi-center Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

The primary objective in this study is to collect post-marketing information on Riociguat safety.Thus, the information on adverse events (AEs) and adverse drug reactions (ADRs) that occur within the first 12 months and in the following 6 -year observation at most, after starting Riociguat treatment under the routine clinical practice …

adempas
pulmonary arterial hypertension
riociguat
  • 10 views
  • 04 Aug, 2021
  • 1 location
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Background High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover …

pulmonary function test
hypertension
walk tests
left ventricular end-diastolic pressure
pulmonary arterial hypertension
  • 49 views
  • 03 Aug, 2021
  • 1 location